Flavonoid binding to human serum albumin

Biochemical and Biophysical Research Communications

Volumn 398, Issue 3, 2010, Pages 444-449

  Bolli, Alessandro ^a   Marino, Maria ^a   Rimbach, Gerald ^b   Fanali, Gabriella ^c   Fasano, Mauro ^c   Ascenzi, Paolo ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Allostery; Daidzein; Daidzein metabolites; Flavonoid binding; Genistein; Human serum albumin; Naringenin; Oleate; Quercetin; Thermodynamics

Indexed keywords

4' DAIDZEINSULFATE; 4',7 DAIDZEINDISULFATE; 6,3' DIHYDROXYDAIDZEIN; 7 DAIDZEINSULFATE; 8 HYDROXYDAIDZEIN; 8,3' DIHYDROXYDAIDZEIN; DAIDZEIN; FLAVONOID; GENISTEIN; HUMAN SERUM ALBUMIN; NARINGENIN; QUERCETIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DIET SUPPLEMENTATION; DRUG PROTEIN BINDING; EQUILIBRIUM CONSTANT; HUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION;

BIOLOGICAL AVAILABILITY; DIET; FLAVANONES; FLAVONOIDS; GENISTEIN; HUMANS; ISOFLAVONES; OLEIC ACID; PROTEIN BINDING; PROTEIN CONFORMATION; QUERCETIN; SERUM ALBUMIN;

EID: 77955276013     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.096     Document Type: Article

References (47)

1. Sudlow G., Birkett D.J., Wade D.N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 1975, 11:824-832.
2. All about Albumin: Biochemistry, Genetics and Medical Applications 1996, Academic Press, San Diego and London. T. Peters (Ed.).
3. Kragh-Hansen U., Chuang V.T., Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 2002, 25:695-704.
4. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 2005, 353:38-52.
5. Fasano M., Curry S., Terreno E., Galliano M., Fanali G., Narciso P., Notari S., Ascenzi P. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005, 57:787-796.
6. Ascenzi P., Bocedi A., Notari S., Fanali G., Fesce R., Fasano M. Allosteric modulation of drug binding to human serum albumin. Mini Rev. Med. Chem. 2006, 6:483-489.
7. Zunszain P.A., Ghuman J., Komatsu T., Tsuchida E., Curry S. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct. Biol. 2003, 3:6.
8. Ascenzi P., Fasano M. Serum heme-albumin: an allosteric protein. IUBMB Life 2009, 61:1118-1122.
9. Sugio S., Kashima A., Mochizuki S., Noda M., Kobayashi K. Crystal structure of human serum albumin at 2.5Å resolution. Protein Eng. 1999, 12:439-446.
10. Ascenzi P., Fasano M. Allostery in a monomeric protein: the case of human serum heme-albumin. Biophys. Chem. 2010, 148:16-22.
11. Curry S., Mandelkov H., Brick P., Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 1998, 5:827-835.
12. Bhattacharya A.A., Curry S., Franks N.P. Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. J. Biol. Chem. 2000, 275:38731-38738.
13. Bhattacharya A.A., Grüne T., Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol. 2000, 303:721-732.
14. Petitpas I., Bhattacharya A.A., Twine S., East M., Curry S. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J. Biol. Chem. 2001, 276:22804-22809.
15. Chuang V.T.G., Otagiri M. How do fatty acids cause allosteric binding of drugs to human serum albumin?. Pharm. Res. 2002, 19:1458-1464.
16. Hamilton J.A. Fatty acid interactions with proteins: what X-ray crystal and NMR solution structures tell us. Prog. Lipid. Res. 2004, 43:177-199.
17. Curry S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab. Pharmacokinet. 2009, 24:342-357.
18. Galluzzo P., Marino M. Nutritional flavonoids impact on nuclear and extranuclear estrogen receptor activities. Genes Nutr. 2006, 1:161-176.
19. Marino M., Bulzomi P. Mechanisms at the root of flavonoid action in cancer: a step toward solving the Rubik's cube. Flavonoids: Biosynthesis Biological Effects and Dietary Sources 2009, 231-248. Nova Science Publishers, New York. R.B. Keller (Ed.).
20. Virgili F., Marino M. Regulation of cellular signals from nutritional molecules: a specific role for phytochemicals, beyond antioxidant activity. Free Radic. Biol. Med. 2008, 45:1205-1216.
21. Medić-Sarić M., Rastija V., Bojić M., Males Z. From functional food to medicinal product: systematic approach in analysis of polyphenolics from propolis and wine. Nutr. J. 2009, 8:33.
22. Rimbach G., De Pascual T.-S., Ewins B.A., Matsugo S., Uchida Y., Minihane A.M., Turner R., Vafei A.K., Weinberg P.D. Antioxidant and free radical scavenging activity of isoflavone metabolites. Xenobiotica 2003, 33:913-925.
23. Rimbach G., Weinberg P.D., de Pascual T.-S., Alonso M.G., Ewins B.A., Turner R., Minihane A.M., Botting N., Fairley B., Matsugo S., Cassidy A. Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function. Biochim Biophys. Acta. 2004, 1670:229-237.
24. Bocedi A., Notari S., Menegatti E., Fanali G., Fasano M., Ascenzi P. Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. FEBS J. 2005, 272:6287-6296.
25. Mandeville J.S., Froehlich E., Tajmir-Riahi H.A. Study of curcumin and genistein interactions with human serum albumin. J. Pharm. Biomed. Anal. 2009, 49:468-474.
26. Antonini E., Brunori M. Hemoglobin and Myoglobin in their Reactions with Ligands 1971, North Holland Publishing Co., Amsterdam and London.
27. Anderson S.R., Antonini E. The binding of carbon monoxide by human hemoglobin: proof of validity of the spectrophotometric method and direct determination of the equilibrium. J. Biol. Chem. 1968, 243:2918-2920.
28. 2S solubility via the reaction with ferric hemoglobin I from the bivalve mollusc Lucina pectinata. Biochim. Biophys. Acta 2000, 1523:206-208.
29. Goodsell D.S., Olson A.J. Automated docking of substrates to proteins by simulated annealing. Proteins 1990, 8:195-202.
30. Goodsell D.S., Morris G.M., Olson A.J. Automated docking of flexible ligands: applications of autodock. J. Mol. Recogn. 1998, 9:1-5.
31. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem. 1998, 19:1639-1662.
32. Petitpas I., Grüne T., Bhattacharya A.A., Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J. Mol. Biol. 2001, 314:955-960.
33. Schuettelkopf A.W., Van Aalten D.M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:1355-1363.
34. Maes V., Engelborghs Y., Hoebeke J., Maras Y., Vercruysse A. Fluorimetric analysis of the binding of warfarin to human serum albumin: equilibrium and kinetic study. Mol. Pharmacol. 1982, 21:100-107.
35. Bocedi A., Notari S., Narciso P., Bolli A., Fasano M., Ascenzi P. Binding of anti-HIV drugs to human serum albumin. IUBMB Life 2004, 56:609-614.
36. Sułkowska A., Bojko B., Równicka J., Sułkowski W. Competition of drugs to serum albumin in combination therapy. Biopolymers 2004, 74:256-262.
37. Ascenzi P., Bocedi A., Notari S., Menegatti E., Fasano M. Heme impairs allosterically drug binding to human serum albumin Sudlow's site I. Biochem. Biophys. Res. Commun. 2005, 334:481-486.
38. Yang J.D., Deng S.X., Liu Z.F., Kong L., Liu S.P. Fluorescence quenching of serum albumin by rifampycin antibiotics and their analytical application. Luminescence 2007, 22:559-566.
39. Fanali G., Rampoldi V., Di Masi A., Bolli A., Lopiano L., Ascenzi P., Fasano M. Binding of anti-Parkinson's disease drugs to human serum albumin is allosterically modulated. IUBMB Life 2010, 62:371-376.
40. Di Bari L., Ripoli S., Pradhan S., Salvadori P. Interactions between quercetin and warfarin for albumin binding: a new eye on food/drug interference. Chirality 2010, 22:593-596.
41. Simard J.R., Zunszain P.A., Hamilton J.A., Curry S. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J. Mol. Biol. 2006, 361:336-351.
42. Galluzzo P., Ascenzi P., Bulzomi P., Marino M. The nutritional flavanone naringenin triggers antiestrogenic effects by regulating estrogen receptor α-palmitoylation. Endocrinology 2008, 149:2567-2575.
43. Crozier A., Jaganath I.B., Clifford M.N. Dietary phenolics: chemistry, bioavailability and effects on health. Nat. Prod. Rep. 2009, 26:1001-1043.
44. Totta P., Acconcia F., Virgili F., Cassidy A., Weinberg P.D., Rimbach G., Marino M. Daidzein-sulfate metabolites affect transcriptional and antiproliferative activities of estrogen receptor-β in cultured human cancer cells. J. Nutr. 2005, 135:2687-2693.
45. Terao J., Kawai Y., Murota K. Vegetable flavonoids and cardiovascular disease. Asia Pac. J. Clin. Nutr. 2008, 17(Suppl 1):291-293.
46. Gade W., Schmit J., Collins M., Gade J. Beyond obesity: the diagnosis and pathophysiology of metabolic syndrome. Clin. Lab. Sci. 2010, 23:51-61.
47. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25:1605-1612.